Skip to main content
Clinical Trials/JPRN-UMIN000014422
JPRN-UMIN000014422
Completed
未知

Prospective and randomized study on the efficacy of novel hypoglycemic type 2 diabetes agent ipragliflozin to serum glycemic control and cardiovascular risk factors - Prospective and randomized study on the efficacy of novel hypoglycemic type 2 diabetes agent ipragliflozin to serum glycemic control and cardiovascular risk factors

Fukui-ken Saiseikai Hospital0 sites100 target enrollmentJune 30, 2014

Overview

Phase
未知
Intervention
Not specified
Conditions
Not specified
Sponsor
Fukui-ken Saiseikai Hospital
Enrollment
100
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
June 30, 2014
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • 1\) With receiving insulin therapy 2\) With a history of ischemic heart disease (angina pectoris, myocardial infarction) and ischemic stroke 3\) Serum Creatinine \>\= 1\.2 mg/dL 4\) Fasting serum triglycerides levels \>\= 400 mg/dL 5\) HbA1c was changed 2% or more within 3 months 6\) With unconscious thirst (impossible self\-judgement water intake) 7\) With contraindication for ipragliflozin a) History of hypersensitivity to ipragliflozin b) Severe ketosis, diabetic or precoma c) Severe infection, pre or post surgery, and severe trauma 8\) Considered as inadequate by the investigator

Outcomes

Primary Outcomes

Not specified

Similar Trials